Agios Pharmaceuticals (MEX:AGIO) Other Current Payables: MXN0 Mil (As of Mar. 2026)


MEX:AGIO Agios Pharmaceuticals Inc MEX:AGIO
49 GF Score
Price MXN1,222.00
GF Value MXN2,369.31
! 5 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Other Current Payables?

Agios Pharmaceuticals MEX:AGIO 49 Other Current Payables is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:AGIO with a GF Score™ of 49/100 and a GF Value™ of MXN2,369.31. The stock has 5 warning signs investors should review.

Agios Pharmaceuticals's Other Current Payables for the quarter that ended in Mar. 2026 was MXN0 Mil.

Agios Pharmaceuticals's annual Other Current Payables increased from Dec. 2023 (MXN0 Mil) to Dec. 2024 (MXN0 Mil) but then declined from Dec. 2024 (MXN0 Mil) to Dec. 2025 (MXN0 Mil).

Agios Pharmaceuticals Other Current Payables Related Terms

Agios Pharmaceuticals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Other Current Payables Chart

Agios Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Agios Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00
MEX:AGIO
49GF Score
Agios Pharmaceuticals Inc MEX:AGIO
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agios Pharmaceuticals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of MXN0 Mil mean?
Agios Pharmaceuticals (MEX:AGIO) has a Other Current Payables of MXN0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Other Current Payables too high?
Agios Pharmaceuticals' current Other Current Payables is MXN0 Mil. Overall, Agios Pharmaceuticals has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Other Current Payables compare to ABCL and KOD?
Agios Pharmaceuticals' Other Current Payables of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Other Current Payables is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (MEX:AGIO) has a current Other Current Payables of MXN0 Mil. The stock's GF Value™ is MXN2,369.31, compared to a current price of MXN1,222.00 — trading 48.4% below its estimated fair value. The current Other Current Payables is MXN0 Mil. Agios Pharmaceuticals' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Agios Pharmaceuticals (MEX:AGIO), the current Other Current Payables is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (MEX:AGIO) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of MXN1,222.00 is trading 48.4% below its estimated GF Value™ of MXN2,369.31.

Key valuation signals for MEX:AGIO:

  • Other Current Payables: MXN0 Mil
  • GF Value™: MXN2,369.31 vs. price of MXN1,222.00 (48.4% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the MEX:AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
49GF Score

Get the complete analysis for MEX:AGIO

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,222.00
Price
MXN2,369.31
GF Value